Transgene Announces Presentation of Data on TG1050 Immunotherapy against Chronic Hepatitis B and Provides Update on its Joint Venture with Tasly Pharmaceuticals in China
Strasbourg, France, July 1st, 2014 - Transgene today announced that it was invited to present existing preclinical data on its proprietary program against chronic hepatitis B, TG1050 immunotherapy, at the BIT 5th Annual International Symposium of Hepatitis in Dalian, China. The presentation, entitled, "TG1050, A Novel Viral-based Immunotherapeutic Targeting Chronic Hepatitis B Infection" was given by Dr. Ren Zhu, Senior Scientist and Head of the HBV Program at TRANSGENE Biopharmaceutical Technology (Shanghai) Co., Ltd, a Transgene subsidiary located in Shanghai, China.
The Company also provided an update on activities at the Company's 50:50 equity joint venture (JV) with Tasly Pharmaceutical Group Co., Ltd. - Transgene Tasly (Tianjin) Biopharmaceutical Co., Ltd. The JV was set up to develop and commercialize innovative targeted immunotherapeutic products for the Chinese market. There are currently three projects ongoing at the joint venture: Transgene's programs TG1050, TG3003, a monoclonal antibody to treat solid tumors and TG6002, an oncolytic viral immunotherapy to treat solid tumors. TG1050 is currently the JV's most advanced program under development in China, with manufacturing process development ongoing and pre-clinical efficacy and toxicity studies anticipated to start later in 2014.